Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers

Pancreas. 2021 Jan 1;50(1):e6-e8. doi: 10.1097/MPA.0000000000001704.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Erdheim-Chester Disease / diagnosis
  • Erdheim-Chester Disease / drug therapy*
  • Erdheim-Chester Disease / enzymology
  • Erdheim-Chester Disease / genetics
  • Female
  • Humans
  • Imidazoles / adverse effects*
  • Male
  • Middle Aged
  • Minnesota
  • Mutation
  • Off-Label Use
  • Oximes / adverse effects*
  • Pancreatitis / chemically induced*
  • Pancreatitis / diagnosis
  • Paris
  • Protein Kinase Inhibitors / adverse effects*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics
  • Retrospective Studies
  • Tertiary Care Centers
  • Treatment Outcome
  • Vemurafenib / adverse effects*

Substances

  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib